Clinical Trial Search

Primary: CRM Performance During First Sim Scenario Assessed by Ottawa Global Rating Scale (GRS) — -0.299 Pearson correlation coefficient — p=0.039

Primary: Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) — 23; 21 genes

Primary: The Prevalence of Reported Aches and Pains in the Last Month Across the 3 Age Groups — 473; 224; 188 participants

Primary: Rate of Participant Long Term Care Planning for Alzheimer's Dementia/Memory Loss — 173 Participants — p=.6539

Primary: Energy Intake Compensation — 1; 1 MJ/day

Primary: Neuropsychological Status (i.e., Cognitive Functioning) — 0.008; .484; -.084; -.482 z-score composites of cognitive domains — p=0.001

Primary: Change in Microbiome — 0; 0; 0 Operational Taxonomic Unit (OTU)

Primary: Change From Baseline in Ra (a dermaTOP Parameter), of Test Product Treated Versus (vs.) Untreated Side at Day 29 — -1.90; -0.12 Micro meter (µm) — p=0.0638

Primary: In-Home Occupational Performance Evaluation (I-HOPE) Activity Score — 0.73; 0.72; 0.76; 0.69 score on a scale — p=0.068

Primary: Telomere Length — 0.96; 1.06; 1.06; 1.22 ratio

Primary: Evaluation of the Change of Baseline Fried Frailty Criteria at 6 Months — 2.3; 1.4 scores on a scale

Primary: World Health Organization Quality of Life-BREF (WHOQOL-BREF) — 86; 82; 3; 3 score on a scale

Primary: Change in Carotid Chemosensitivity Following 4 Weeks of Dietary Nitrate Supplementation and Placebo in Older Adults — -0.13; -0.05; -0.10; -0.11 L/min/%SpO2

Primary: Collection of Imaging of BAT by Magnetic Resonance Imaging — 78.69; 82.58; 82.45 Percentage

Primary: Peri- and Postoperative Time Course of Circulating 1,25-dihydroxyvitamin D in the First Postoperative Month in Cardiac Surgery Patients — 13; 4.2 percentage

Primary: Pilot Evaluation - Percentage of Participants Retained at Follow up — 10; 10; 9; 11 Participants

Primary: Dependence in Two or More Activities of Daily Living (ADL) — 35; 26; 44 participants — p=<0.05

Primary: Area Under the Curve for Oral Glucose Tolerance Test (oGGT) — 10.8; 11.0; 9.9; 10.6 mM h

Primary: Time to Rise From a Chair 10 Times (Modified From the Original Short Physical Performance Battery) — -20; -20; -8; -10 percentage change

Primary: Immunological Responses — 8.33; 11.24 cells/mm^3 — p=0.56

Primary: Change in Quality of Life Assessed Using the Older People's Quality of Life Questionnaire (OPQOL-brief). — 43.33 score on a scale

Primary: Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index — 1.91; 0.84 units on a scale — p=0.001

Primary: Change in Markers of Immune Senescence Between Baseline Values and Values After 12 Weeks of Supplementation — 1.87; 4.22; -2.83; -1.56 percentage of cells — p=< 0.05

Primary: Hamilton Depression Rating Scale. — 8.09 units on a scale

Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids

Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec

Primary: Egg Intake — 5; 4 eggs

Primary: Lean Mass — 403 grams

Primary: Cutaneous Blood Flow Response to Local Heating of the Skin. — 68; 70 percent change in mean skin blood flow

Primary: Arterial Stiffness — 7.8; 10.0 m/s